ExodusPoint Capital Management LP Acquires Shares of 215,137 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

ExodusPoint Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 215,137 shares of the company's stock, valued at approximately $2,726,000. ExodusPoint Capital Management LP owned approximately 0.21% of Day One Biopharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in DAWN. Frazier Life Sciences Management L.P. purchased a new position in shares of Day One Biopharmaceuticals in the third quarter valued at about $9,607,000. Pictet Asset Management Holding SA lifted its holdings in Day One Biopharmaceuticals by 17.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock worth $44,219,000 after purchasing an additional 507,398 shares in the last quarter. Wellington Management Group LLP boosted its stake in Day One Biopharmaceuticals by 142.1% in the 3rd quarter. Wellington Management Group LLP now owns 721,581 shares of the company's stock worth $10,052,000 after purchasing an additional 423,543 shares during the period. Norges Bank purchased a new stake in Day One Biopharmaceuticals during the 4th quarter valued at approximately $2,141,000. Finally, Geode Capital Management LLC raised its position in shares of Day One Biopharmaceuticals by 10.5% during the third quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company's stock valued at $19,961,000 after buying an additional 136,458 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the sale, the chief financial officer now directly owns 252,638 shares in the company, valued at approximately $3,021,550.48. This represents a 1.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares of the company's stock, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock worth $251,925 over the last quarter. Insiders own 8.40% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities analysts recently weighed in on DAWN shares. Needham & Company LLC restated a "buy" rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. dropped their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, March 25th. HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Finally, Bank of America dropped their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.29.

Day One Biopharmaceuticals Stock Up 5.3 %

DAWN traded up $0.36 on Friday, hitting $7.12. The company had a trading volume of 1,297,624 shares, compared to its average volume of 1,117,362. The business's fifty day simple moving average is $9.33 and its 200 day simple moving average is $12.05. Day One Biopharmaceuticals, Inc. has a 12-month low of $6.41 and a 12-month high of $18.07. The company has a market cap of $721.65 million, a PE ratio of -6.91 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million. On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.